Grace Miller was a 24-year-old law school student when she was diagnosed with multiple sclerosis ...

As recently as the ‘90s, when patients arrived with all the typical symptoms — memory loss, double vision, fatigue — neurologists often avoided confirming what they most suspected: that the patient ...

During MS Awareness Month, a Groundbreaking Research-and-Care Model Looks Back on 20 Years of Firsts I am eager to see ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...

The discovery could open up new ways for treating diseases such as MS by leveraging molecules that are already present in the human body. The post Gene yaks have could inspire new multiple sclerosis ...

Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

A second clinical trial testing fenebrutinib for MS has met its main goal, once again beating approved Aubagio in reducing ...

Multiple sclerosis (MS) is a debilitating autoimmune disease of the brain and spinal cord. The disease can affect everyone differently, but depending on the progression and severity of the disease, ...

Significantly higher levels of HRQoL were reported in patients who lived in cities, had lower MS severity and fatigue, had higher cognitive processing speed, and had achieved higher educational ...

Patients with multiple sclerosis (MS) who were receiving disease-modifying therapies were found to have rare occurrences of severe COVID-19 if they had received the vaccine, according to a study ...

PARIS — The first real guidelines on the use of disease-modifying therapies in multiple sclerosis (MS) have been released by a European joint venture between the European Committee for Research and ...